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Abstract
Introduction: Asthma, a respiratory disease associated with airway inflammation and hyperresponsiveness, is one of the most prevalent
chronic diseases worldwide affecting both children and adults. Inhaled corticosteroids are considered to be the cornerstone of asthma
management. Ciclesonide, an airway-activated inhaled corticosteroid, has been developed for the management of persistent asthma.
Its once-daily administration and airway activation may be advantageous in the treatment of asthma.
Aims: The purpose of this article is to review the place in therapy of ciclesonide in the management of patients with persistent asthma
based on the available clinical evidence. 
Evidence review: The available evidence indicates that ciclesonide has an effect on pulmonary function (forced expiratory volume in
1 s, forced vital capacity, and peak expiratory flow), as well as producing improvements in patient-reported symptoms that are equivalent
to those achieved with other inhaled corticosteroids. A few studies have focused on health-related quality of life and have demonstrated
a positive effect with ciclesonide treatment. Its pharmacokinetic profile may offer advantages in terms of adverse effects, both local and
systemic, although most of the data come from 12-week studies.
Place in therapy: The current evidence shows that ciclesonide offers another alternative among inhaled corticosteroids, with the
potential for fewer adverse effects. The unique pharmacokinetic profile of ciclesonide allows once-daily administration and the airway
activation of the drug appears to confer clinical benefit in the treatment of asthma. Its lack of systemic adverse effects make it a viable
option for pediatric use.
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Outcome measure Evidence Implications
Patient-oriented evidence
Improvement in asthma symptoms Clear Effects are similar to other inhaled corticosteroids
Reduction in rescue medication Clear Effects are similar to other inhaled corticosteroids
Improvement in quality of life Substantial Beneficial effects on patient-perceived quality of life
Reduction in oral corticosteroid use Moderate Reduction in the regular use of oral corticosteroids likely to decrease the incidence of
adverse systemic effects
Disease-oriented evidence
Preservation of hypothalamic–pituitary–adrenal axis Substantial Lack of effect on hypothalamic–pituitary–adrenal axis for up to 1 year; suitable for use
in pediatric patients
Lower incidence of local adverse effects Clear Fewer local adverse effects (e.g. oropharyngeal effects) compared with other inhaled
corticosteroids
Improvement in lung function (FEV1, FVC, PEF) Clear Ciclesonide as effective as budesonide and fluticasone, at least in the short term 
Economic evidence
Cost effectiveness as an inhaled corticosteroid in
persistent asthma in adults and children
No evidence Evidence required
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; PEF, peak expiratory flow.
Core evidence place in therapy summary for ciclesonide in persistent asthmaScope, aims, and objectives
Ciclesonide (Alvesco®, ALTANA Pharma AG), an airway-activated
inhaled corticosteroid, has been developed for the management
of persistent asthma. Its once-daily administration and airway
activation may be advantageous in the treatment of asthma.
Pharmacologically, the activation of ciclesonide to its active
metabolite, desisobutyryl-ciclesonide (des-CIC), by airway
esterases is novel. This local activation of drug provides
concentrated activity of ciclesonide at the target organ, the lungs,
and may decrease the potential for local and systemic adverse
effects. Data from phase III clinical trials evaluating ciclesonide in
the management of adult and pediatric patients with persistent
asthma are available.
The purpose of this article is to review the place in therapy of
ciclesonide in the management of patients with persistent asthma
based on the available clinical evidence. 
Methods
The English language medical literature was reviewed for
appropriate articles relating to ciclesonide for the treatment of
asthma. The following databases were searched during August
2005 using the search terms “ciclesonide,” “El 876,” “By 90107,”
and “Alvesco”: 
• PubMed, http://www.ncbi.nlm.nih.gov 
• EMBASE, http://www.datastarweb.com
• BIOSIS, http://www.datastarweb.com
• York University Centre for Reviews and Dissemination (CRD)
databases, http://www.york.ac.uk/inst/crd/crddatabases.htm
• National Guideline Clearinghouse, http://www.guideline.gov
• Clinical trial registries, http://www.clinicaltrials.gov,
http://www.clinicalstudyresults.org
• National Coordinating Centre for Health Technology
Assessment (NCCHTA), http://www.ncchta.org
• Cochrane Database of Systematic Reviews (CDSR),
http://www.cochrane.org/index0.htm
• National Institute for Health and Clinical Evidence (NICE),
http://www.nice.org.uk
• Clinical Evidence (BMJ), http://www.clinicalevidence.com
No date limitations were placed on the search and only studies in
patients with asthma were included. Abstracts from the American
Thoracic Society (ATS) (http://www.thoracic.org) and the
European Respiratory Society (ERS) meetings
(http://www.ersnet.org/ers) for 2002–2005 were also reviewed
using the same search terms to identify studies that have not yet
been published in full. 
Numerous guidelines related to asthma management were
identified, but only two recent guidelines applicable on a global
level were considered relevant for this review. No studies were
identified from a review of clinical trials databases. A single Health
Technology Assessment of ciclesonide was identified from the
York University Centre.
The levels of evidence identified from the literature searches are
summarized in Table 1. Twenty full papers were identified in the
initial search. Records were manually reviewed and 12 papers
were excluded: pharmacokinetic (n=5), in vitro (n=1), animal
studies (n=2), study other than a large, controlled clinical trial
(n=3), or citations that mentioned ciclesonide but did not
investigate its clinical use (n=1). Sixty-one abstracts were also
reviewed manually. Exclusions included: published in full (n=4),
pharmacokinetic (n=5), animal studies (n=6), in vitro (n=10), study
other than a large, controlled clinical trial (n=11), and
presentation of study results at more than one professional
meeting (n=6).
The search was updated on February 7 and on June 30, 2006 and
22 new records were identified from the previous search. Eleven
records were excluded as they were nonsystematic reviews (n=6),
editorials (n=1), in vitro (n=2), small pharmacokinetic study (n=1), 
or an indication other than asthma (n=1). A systematic review 
(Dyer et al. 2006) was not included in the evidence base, as it 
was limited to small phase II studies comparing ciclesonide with
other inhaled corticosteroids, rather than more recent larger
phase III randomized controlled trials (RCTs). 
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Category Number of records
Full papers Abstracts
Initial search 20 61
records excluded 12 42
records included 81 9
Additional studies identifieda 33
Search update, new records 22 22
records excluded 12 18
records included 10 4
Level 1 clinical evidence 2 0
Level 2 clinical evidence 18 27b
Level ≥3 clinical evidence 1 0
trials other than RCT 1
case reports
Economic evidence 0 0
Total records included 21 27
aAdditional studies identified = any relevant study that was picked up from a source other
than the main searches, e.g. a reference list.
bIncludes several subanalyses from six RCTs.
For definitions of levels of evidence see Editorial Information on inside back cover.
RCT, randomized controlled trial.
Table 1 | Evidence base included in the review235
In addition, a further level 3 pharmacokinetic study was identified
and included (Nave et al. 2006), along with 22 abstracts of
meeting presentations, of which 4 were included following removal
of duplicates.
Disease overview
Asthma, a chronic respiratory disease of both children and adults,
is one of the most prevalent chronic diseases in the world affecting
approximately 300 million people (Bousquet et al. 2005; Masoli 
et al. 2005). An estimated 250 000 deaths caused by asthma occur
annually; one in every 250 deaths worldwide is thought to be
secondary to asthma (Bousquet et al. 2005; Masoli et al. 2005).
The impact of asthma is far-reaching in both the adult and
pediatric population and includes an effect on activities of daily
living that extends to participation in school, work, and family life.
Globally, about 15 million disability-adjusted life years (DALYs) are
lost annually due to asthma, a number similar to that associated
with diabetes, cirrhosis, or schizophrenia (Masoli et al. 2005).
Direct medical costs related to medications and hospital
admissions, and indirect medical costs related to loss of work and
premature mortality are significant. Direct medical costs of
asthma treatment account for up to 3% of total medical
expenditures for many countries (Bousquet et al. 2005). 
Although the exact etiology of asthma remains poorly understood
it is thought to have both genetic and environmental causes and
is considered a chronic inflammatory disease. Asthma is
characterized by bronchial hyperreactivity caused by chronic
inflammation of the airways. Bronchial hyperreactivity is
associated with reversible airflow obstruction and episodes of
wheezing, breathlessness, chest tightness, and coughing
(especially in the early morning or at night). There is no cure for
asthma and the goal of treatment is to achieve and maintain
control of symptoms, prevent exacerbations, reduce/eliminate
side effects from medications, and allow patients to have an
optimal quality of life. The potential for development of adverse
effects associated with asthma treatment has been noted to
impact patient adherence to therapy (Goeman 2002).
Current therapy options
Over the past two decades the treatment of asthma has received
increased attention and guidelines for the management of asthma
have been published [Global Initiative for Asthma (GINA) strategy,
World Health Organization (WHO)/National Heart, Lung, and
Blood Institute (NHLBI); Anon. 2005b). A global strategy for
asthma management and prevention—the result of a
collaborative effort of GINA, WHO, and the NHLBI—was first
issued in 1995. Updates to this guideline have been released with
the most recent being in 2004. Asthma management protocols
and guidelines focus on the inflammatory component of the
disease and recommend a stepped-care approach to disease
management (Table 2). 
Many pharmacologic entities are available for the chronic
management of persistent asthma, but inhaled corticosteroids are
the cornerstone of therapy. Corticosteroids can be administered
either orally or via inhalation, although the adverse effect profile
significantly favors the latter. Inhaled corticosteroids are
considered the most effective therapy for persistent asthma and
are the preferred treatment for all patients with persistent disease
symptoms (Anon. 2005b). 
All of the available inhaled corticosteroids produce their effects by
interacting with intracellular glucocorticoid receptors, which are
present throughout the body. In the treatment of asthma, the effect
of these agents on pulmonary glucocorticoid receptors produce
the desired effects but interaction with glucocorticoid receptors
outside the lungs can lead to unwanted adverse effects such as
suppression of the hypothalamic–pituitary–adrenal axis (HPA),
reduction of bone density, and growth suppression. Beneficial
pharmacologic effects of these agents include decreasing
inflammatory cells in the airway and increasing the release of
antiinflammatory cytokines (Hübner et al. 2005). The decrease in
inflammatory mediators results in a reduction of airway
inflammation and hyperreactivity, improved pulmonary function,
symptom control, and reduction of exacerbations (Kelly 2003). 
The principal goal of inhaled corticosteroid therapy is to have a
high level of antiinflammatory effect with minimal adverse effects
(Kelly 2003). Although differences in pharmacokinetic parameters
and potency exist, the currently available agents (Table 3) are
considered equally efficacious when administered at equipotent
doses (O'Connell 2005). The ideal inhaled corticosteroid for
patients with asthma has a high degree of lung deposition with a
low level of systemic bioavailability providing therapeutic benefit
(high glucocorticoid receptor affinity) without significant adverse
effects. Systemic exposure can be minimized by high protein
binding and a rapid clearance rate (Berger 2005). Use of a
prodrug that is not pharmacologically active until it undergoes a
metabolic transformation has been shown to decrease
oropharyngeal effects and might result in improved pulmonary
targeting (Hübner et al. 2005).
Smaller particle size, physical properties of the compounds,
delivery device used, and inhaler technique all have an impact on
the rate of lung deposition (Hübner et al. 2005). Higher rates of
lung deposition translate to an increased amount of drug available
at the intended site of action (lungs) and a lower amount available
for oral absorption and systemic availability, and hence fewer
adverse effects. In addition, lipid conjugation of the compound
can provide a reservoir in the lungs allowing for a slow release of
active compound (Berger 2005).
Of particular concern for long-term treatment of persistent
asthma is an agent’s propensity to cause systemic side effects.
Systemic exposure to an inhaled corticosteroid is tied to its
potential for adverse effects. There is little concern about
systemic effects with the use of low-dose inhaled corticosteroids
(doses of ≤500 mcg budesonide or equivalent) (Anon. 2005b).
However, at high doses concern remains that these medications
may cause HPA axis suppression, decreased bone mineralization,
cataracts, glaucoma, and a reduction in the rate of bone growth
in children. It is important to note that while HPA axis suppression
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Category of asthma Characteristics Daily medicationa
Adults and children >5 years
Intermittent • Symptoms <once/week 
• Brief exacerbations
• Nocturnal symptoms ≤2 nights/month
• FEV1 or PEF ≥80% predicted
• PEF or FEV1 variability <20%
• None
Mild persistent • Symptoms >once/week, but <once/day 
• Exacerbations may affect activity and sleep
• Nocturnal symptoms >2 nights/month
• FEV1 or PEF ≥80% predicted
• PEF or FEV1 variability 20–30%
• Low-dose inhaled corticosteroid
• Alternative: cromolyn, leukotriene modifier,
nedocromil, or sustained-release theophylline
Moderate persistent • Daily symptoms
• Exacerbations may affect activity and sleep
• Nocturnal symptoms >once/week
• Daily use of short-acting inhaled beta2 agonist
• FEV1 or PEF 60–80% predicted
• PEF or FEV1 variability >30%
• Low to medium-dose inhaled corticosteroid and
long-acting inhaled beta2 agonist
• Alternative:
– Increase inhaled corticosteroid within medium
dose range
or
– Low to medium-dose inhaled corticosteroid and
either leukotriene modifier or theophylline
Severe persistent • Continuous symptoms
• Frequent exacerbations 
• Frequent nocturnal symptoms 
• Limitation of physical activities
• FEV1 or PEF 60% predicted
• PEF or FEV1 variability >30%
• High-dose inhaled corticosteroid and long-acting
inhaled beta2 agonist
• If needed: oral corticosteroid, sustained-release
theophylline, leukotriene modifier,
antiimmunoglobulin E antibody (adults and
children ≥2 years)
Infants and young children <5 years
Mild intermittentb • Symptoms <once/week 
• Brief exacerbations
• Nocturnal symptoms <2 nights/month
• FEV1 or PEF ≥80% predicted
• PEF or FEV1 variability <20%
• None
Mild persistent • Symptoms >once/week, but <once/day 
• Exacerbations may affect activity 
• Nocturnal symptoms >2 nights/month
• FEV1 or PEF ≥80% predicted
• PEF or FEV1 variability 20–30%
• Low-dose inhaled corticosteroid
• Alternative: cromolyn, leukotriene modifier,
nedocromil, or sustained-release theophylline
Moderate persistent • Daily symptoms
• Exacerbations affect activity 
• Nocturnal symptoms >once/week
• FEV1 or PEF 60–80% predicted
• PEF or FEV1 variability >30%
• Low-dose inhaled corticosteroid and long-acting
inhaled beta2 agonist (if needed medium dose can
be used)
or
• Medium-dose inhaled corticosteroid
• Alternative: low-dose inhaled corticosteroid
(if needed medium dose can be used) and
leukotriene modifier or theophylline
Severe persistent • Continuous symptoms
• Frequent nocturnal symptoms 
• Limitation of physical activity
• FEV1 or PEF ≤60% predicted
• PEF or FEV1 variability >30%
• High-dose inhaled corticosteroid and long-acting
inhaled beta2 agonist
• If needed: oral corticosteroid
aA short-acting inhaled beta2 agonist should be used as needed to relieve acute symptoms; use should be limited to no more than 3–4 times/day.
bChildren with intermittent asthma but severe exacerbations should be managed as having moderate persistent asthma.
FEV1, forced expiratory volume in 1 s; PEF, peak expiratory flow.
Table 2 | Pharmacologic management of asthma: stepped approach (adapted from Anon. 2005b)237
and decreased osteoblast activity have been reported with high-
dose inhaled corticosteroid therapy, the clinical significance of
these effects is controversial. Additionally, patients receiving high
doses of inhaled corticosteroids may be exposed to intermittent
courses of systemic glucocorticoids that complicate the
assessment of the impact of high-dose inhaled corticosteroid
treatment alone (Anon. 2005b). Of the available inhaled
corticosteroids, comparative studies have shown that
budesonide, mometasone, and fluticasone have a lower potential
to cause systemic effects as compared with beclomethasone
dipropionate and triamcinolone (Crim et al. 2001; Anon. 2005b).
Ideally, once a patient’s symptoms are controlled, the dose of
inhaled corticosteroid should be reduced to the minimum
effective dose to promote safe and cost-effective asthma control
(British Thoracic Society 2005). Unfortunately, this approach is
not always undertaken and patients are not infrequently exposed
to unnecessarily high doses and an increased risk of adverse
effects (O'Connell 2005).
Beyond the specific drug selected, the device used to deliver the
therapeutic entity can have a profound effect on treatment
outcome. In an attempt to maximize drug delivery to the lungs, a
variety of inhaler devices have been developed. The device also
impacts the efficacy of therapy and has associated advantages
and disadvantages (Table 4). The delivery device as well as the
specific drug evaluated and the dose selected must all be
considered when evidence of inhaled corticosteroid efficacy and
adverse effects are taken into account. Environmental concerns
have mandated alternatives to the use of chlorofluorocarbon
(CFC) propellants in metered-dose inhalers. The change to
hydrofluoroalkane propellants has resulted in some products that
have different characteristics from previous formulations
(Dolovich et al. 2005). Therefore, interpretation of reported
efficacy and adverse effect data also requires an understanding of
the propellant used.
Even at low daily doses, local adverse effects (dysphonia, oral
candidiasis, and pharyngitis) to inhaled corticosteroids are
reported at widely varying rates (5–58%) (Roland et al. 2004). The
reported prevalence of these local effects is influenced by the
type of study, length of observation, delivery device used, and
method for recording (questionnaire or clinical examination). Local
adverse effects may complicate treatment and lead to a
disruption of therapy and worsening of disease. 
Despite advances in delivery device and drug development, there
is still a need for inhaled corticosteroid therapies that are highly
specific to the site of action, the lungs, with minimal systemic
absorption. Ciclesonide was developed in response to this need. 
Clinical evidence with ciclesonide in asthma
Level 2 evidence from fully published studies investigating the
efficacy and safety of ciclesonide is available, including placebo-
controlled studies (Chapman et al. 2005; Langdon et al. 2005;
Pearlman et al. 2005; Bateman et al. 2006b; Gelfand et al. 2006)
and trials with active comparator (Buhl et al. 2005a; Niphadkar et
al. 2005; Boulet et al. 2006a; Hansel et al. 2006). Further evidence
is also currently available in abstract form only, hindering full
critical appraisal. Outcomes studied include disease-oriented
measurable endpoints of respiratory function, inflammatory
markers, and HPA suppression, as well as patient-oriented
outcomes such as asthma symptoms, health-related quality of life
(HRQOL), and use of rescue medication. Comparator drug
propellant is not consistently reported which makes an
assessment of delivery device difficult.
Ciclesonide is a prodrug whereas the other inhaled
corticosteroids are delivered to the site of action in their active
form. Ciclesonide is converted to its active and highly potent
metabolite, des-CIC, by esterases in the airways, thus providing
active drug at the intended site of action. Ciclesonide is also
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Drug Lung deposition
(MDI-HFA) (%)
Oral
bioavailabilitya (%)
Protein binding (%) Metabolism Excretion Suggested dosing
frequency
Beclomethasone
propionate
51b 26 87 Hepatic Feces, urine (<10%) Twice daily
Budesonide 28 11–32 88 Hepatic Urine (60%), feces Once or twice dailya
Ciclesonide 52 <1 99 Hepatic Feces (77.9%) Once daily
Flunisolide 39 7 80 Hepatic Renal (50%), feces (40%) Twice daily
Fluticasone
propionate
16  <1 90 Hepatic Feces (urine <0.02%) Twice daily
Mometasone furoate – 11 98–99 Hepatic Feces (74%), urine (8%) Once or twice daily
Triamcinolone
acetonide
22b 21.5 71 Mostly hepatic,
some renal
Urine (40%), feces (60%) Twice daily
aDepends on the delivery device used.
bDelivery device not specified.
MDI-HFA, metered-dose inhaler with hydrofluoroalkane propellant.
Table 3 | Pharmacokinetic profiles of currently available inhaled corticosteroids (Reynolds & Scott 2004; Anon. 2005a; Hübner et al.
2005; Wickersham & Novak 2005)formulated in solution which in comparison with suspensions is
likely to improve lung deposition characteristics (Berger 2005). In
addition, other properties of ciclesonide and des-CIC, including
low oral bioavailability (<1%), rapid systemic clearance and a high
degree of plasma protein binding (99%) are designed to reduce
the potential for systemic side effects. 
Therefore, the pharmacologic and pharmacokinetic characteristics
of ciclesonide are intended to provide advancements in the
treatment of asthma with a potentially improved safety profile. 
Systemic absorption
In human lung tissue, a reversible lipid conjugation of des-CIC has
been demonstrated. This may account for the prolonged
antiinflammatory activity of inhaled ciclesonide in the lungs as this
conjugated des-CIC may act as a reservoir (Berger 2005). 
The small particle size of ciclesonide improves its pulmonary
deposition; studies have shown that up to 52% of an inhaled dose
of ciclesonide is deposited in the small airways and alveoli
following administration, and that the amount of deposition is not
influenced by the use of a spacer device (Drollmann et al. 2006;
Newman et al. 2006). The pharmacokinetics of ciclesonide and
des-CIC are similar in healthy subjects and in patients with asthma,
confirming that airway activation of the drug is unimpaired by the
disease (Nave et al. 2006).
Compared with fluticasone and budesonide, smaller amounts of
ciclesonide are available for systemic absorption through the
gastrointestinal tract as lower amounts are deposited in the mouth
and oropharynx. In a study of adults with bronchial asthma, the
oropharyngeal deposition of ciclesonide was about 50% of that
reported with fluticasone propionate, with 90% less des-CIC
present in the oropharyngeal cavity compared with fluticasone
following inhalation (Richter et al. 2005). Following administration of
ciclesonide and budesonide to healthy volunteers, the maximal
concentrations of ciclesonide and des-CIC recovered from
oropharyngeal wash were 30% and 0.67% of budesonide,
respectively (Nave et al. 2005a). Ciclesonide and budesonide
concentrations in the wash decreased rapidly within 15 min of
administration. The concentrations of des-CIC in the oropharynx 60
min after inhalation were only 4% of the budesonide concentration
(Nave et al. 2005a), and 8% of the fluticasone concentration
(Richter et al. 2005). 
Ciclesonide undergoes first-pass hepatic inactivation (>99%)
following oral administration, rendering systemic bioavailability from
the oral route essentially negligible (Nave et al. 2004). Furthermore,
there is a low potential for adverse systemic side effects with inhaled
ciclesonide as it is highly protein bound (>99%) and a low fraction of
unbound active metabolite is available in the systemic circulation
(Rohatagi et al. 2005). The unbound fraction is also rapidly cleared
further limiting systemic availability (Berger 2005). 
Pulmonary function
Laboratory measures of forced expiratory volume in 1 s (FEV1),
forced vital capacity (FVC), and peak expiratory flow (PEF) provide
a direct, objective measure of treatment effect on airflow limitation
in asthma. Use of a spirometer to assess FEV1 and FVC is helpful
for diagnosing and monitoring the progress of asthma and
response to therapy. Measurement of PEF with a peak expiratory
flow meter can provide additional asthma monitoring information.
However, PEF measures are not interchangeable with FEV1 and
FVC, and do not always correlate with asthma severity; the
relationship between FEV1 and PEF and asthma severity, airway
inflammation, and HRQOL is complex and not well established. 
Initial phase II studies documented a decrease in airway
hyperresponsiveness after adenosine monophosphate (AMP)
challenges with ciclesonide therapy; efficacy was similar to that of
both fluticasone and budesonide (Taylor et al. 1999; Kanniess et
al. 2001; Lee et al. 2004; Derom et al. 2005). 
In placebo-controlled trials, ciclesonide demonstrated
improvements in pulmonary function over a range of doses in
patients with asthma with varying degrees of severity from mild to
severe (Table 5). Single daily ciclesonide doses of at least 80 mcg
daily were associated with significant improvements from
baseline in pulmonary function compared with placebo (Langdon
et al. 2005). Studies comparing single daily ciclesonide doses 
of 800 and 1600 mcg have not demonstrated superiority of the
higher dose regimen (Chapman et al. 2002; O'Connor et al.
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Device Advantages Disadvantages
Pressurized metered-dose inhaler  No contamination
Dose–dose reproducibility
Some can be used with breath-actuated
mouthpiece
Requires coordination and good technique
High pharyngeal deposition
Difficult to determine remaining dosage
Holding chamber, spacers Decreased need for patient coordination
Decreased pharyngeal deposition
Added expense
Less portable than metered-dose inhaler alone
Dose delivered might be reduced
Dry-powder inhalers Less patient coordination required: breath actuated
No propellant required
Dose counters in most newer dosage forms
Can deliver high pharyngeal deposition
Moderate to high inspiratory flow required for
actuation
Table 4 | Advantages and disadvantages of portable delivery devices for inhaled corticosteroids (Dolovich et al. 2005)239
2002). More recent data, however, show that compared with
ciclesonide 160 mcg once daily, ciclesonide 320 mcg twice daily
resulted in significantly improved PEF (P=0.0014) in 680 patients
with severe asthma (Bateman et al. 2006a). A dose–response
effect was also demonstrated in a 3-week study investigating
ciclesonide 40, 80, 160, and 320 mcg on exercise-induced
bronchoconstriction in 26 patients with mild asthma (Subbarao
et al. 2006). Daily dosing given either in the morning or in the
evening is associated with positive treatment response 
(Postma et al. 2001).
Ciclesonide 80 mcg has also been shown to block allergen-
induced lung function responses and measures of airway
inflammation in patients with mild atopic asthma (Gauvreau et al.
2005). In this randomized three-way crossover study 21 patients
were treated with ciclesonide 40 or 80 mcg or placebo for 7 days
and challenged with inhaled allergen. Compared with placebo,
ciclesonide 80 mcg/day attenuated the allergen-induced airway
response (P<0.025), the sustained fall in FEV1 measures 24 hours
postchallenge (P<0.025), and the allergen-induced accumulation
of eosinophils into the airways (P<0.025). Similarly, after 4 weeks
of treatment with ciclesonide 160 mcg once daily, inflammatory
response as assessed by AMP bronchial challenge, exhaled nitric
oxide, and sputum eosinophil count was significantly reduced in
17 patients with asthma (Wilson et al. 2006).
In larger studies comparing ciclesonide treatment with an active
control, significant improvements in airflow (changes in FEV1 and
FVC) were reported with ciclesonide and active control in all
studies—with the exception of Boulet et al. (2006a) (Table 6).
Neither treatment with budesonide nor ciclesonide resulted in
improved FEV1 or FVC; however, the decrease in FVC was
significantly less with ciclesonide than with budesonide (P=0.01).
The decline in FEV1 seen with both drugs was expected, since 
all patients routinely required “moderate” doses of inhaled
corticosteroids to control their asthma, were poorly controlled,
and had received budesonide 1280 mcg/day during a 2- to 
4-week run-in phase, which was stopped prior to randomization
to the study regimens. A subsequent abstract by the same
authors reported that treatment with ciclesonide 320 mcg once
daily and fluticasone propionate 200 mcg twice daily improved
FEV1 to a comparable degree (171 mL and 186 mL, respectively;
P<0.0001 vs baseline) (Boulet et al. 2006b). 
PEF values were also significantly improved from baseline with
ciclesonide and active treatment (Table 6). In one study comparing
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Treatment (mcg) n Baseline FEV1
(% of predicted)
Outcome Reference
FEV1 (mL) FEV1 (%) change
from baseline
FVC (mL) Morning PEF (L/min)
CIC 160 qd 
CIC 640 qd
Placebo
107
112
110
60–90 Maintained with
both dosesa
–144
NR +59
+9
–161
Stable for both doses
(P<0.0001)
–29
Chapman et al.
2005
CIC 80 qd 
CIC 320 qd  
Placebo 
120
115
125
60–95 +130 (P=0.0044)b
+190 (P=0.0001)b
–30
NR +190 (P=0.0203)b
+200 (P=0.0197)b
+40
+2c (P=0.0012)b
+3c (P=0.0006)b
–18
Langdon et al.
2005
CIC 80 qd
CIC 160 qd
CIC 320 qd
Placebo
257
250
255
249
60–85 +280 (P≤0.0007)b
+290 (P≤0.0007)b
+310 (P≤0.0007)b
+170
NRN R 10.93c (P=0.0003)b
21.06c (P<0.0001)b
17.22c (P<0.0001)b
–1.70c
Pearlman et al.
2005
CIC 320 bidd
CIC 640 bidd
Placebod
47
49
45
40–80 Trend toward higher
valuese
NR
NR
NR
NR
NR
NR
NR
+4.32b,c 
+15.97b,c
–0.7b,c
Bateman et al.
2006b
All P values vs placebo. 
aP=0.007 for CIC 160 and P=0.0108 for CIC 640.
bReported as a mean value. 
cPEF change from baseline to week 12.
dPatients also received oral prednisone 5–30 mg/day and/or 10–60 mg on alternate days.
eP=0.0237 CIC 320 bid vs placebo, P=0.0277 CIC 640 bid vs placebo.
+, increase over study period; –, decrease over study period; bid, twice daily; CIC, ciclesonide; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; NR, not reported; NS, not
significant; PEF, peak expiratory flow; qd, once daily.
Table 5 | Effect of ciclesonide on lung function in patients with moderate to severe asthma (level 2 evidence; all trials randomized,
double-blind, parallel-group, placebo-controlled, 12 weeks’ duration)Ciclesonide | place in therapy review
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Treatment (mcg)
[duration]
n Baseline
FEV1
(% of
predicted)
Outcome Reference
FEV1 (mL) FEV1 (%) change
from baseline
FVC (mL) Morning PEF
(L/min)
Evening PEF
(L/min)
CIC 320 qd 
BUD 400 qd
[12 w]
399
a 50–90 +411c
+319c
CIC>BUD
(P=0.0374)
NR Increase in both
groups (no values
given); CIC>BUD
(P=0.0359)
NR NR Biberger
et al. 2003
CIC 160 qd
FP 88 bid
[12 w]
266
263
80–100 +489c
+499c
+20.45
+20.4
+530c
+499c
+33c
+36c
NR Buhl et al.
2005a
CIC 160 qd A
CIC 160 qd P
BUD 200 bid
[12 w]
139
131
133
≥70 –36d
(P=0.383)
+22d
(P=0.598)
0
NR +5d (P=0.905)
+2d (P=0.970)
0
–4.4d (P=0.464)
+9.3d (P=0.131)
0
–1.1d (P=0.855)
+4.0d (P=0.490)
0
Niphadkar
et al. 2005
CIC 160 bid
CIC 320 bid
FP 440 bidb
Placebo
[12 w]
531a 54 NR +21.24c
+24.46c
+30.09c
NR 18.11c
20.71c
31.73c
–9.69c
NR Weinstein
et al. 2005
CIC 320 qd
CIC 320 bid
BUD 400 bid
[8 w]
319a,e NR NR NR NR +16c
+24c (P=0.001 vs BUD)
+6c
NR Adachi et al.
2006
CIC 320 bid
FP 330 bid
[24 w]
528a,e ≥80 +11
+38
NR NR +36c
+22c
Similar to
morning PEF
(data shown
graphically)
Bateman et
al. 2006c
CIC 320 qd
BUD 320 qd
[12 w]
179
180
65–95 –170
–220
–6
–8
–120 (P=0.01 vs BUD)
–210
–3c
–10c
–2c
–4c
Boulet et al.
2006a
CIC 320 qd
FP 200 bid
[12 w]
472a,e 60–80 +171
+186
NR NR NR NR Boulet et al.
2006b
CIC 80 qd
CIC 320 qd
BUD 200 bid
[12 w]
182
195
177
73c
72c
72c
+267c
+256c
+355c
+10.8
+10.4
+14.4
NR +12c
+17c
+21c
NR Hansel et al.
2006
CIC 640 bid
PRED 40 mg qd
[2 w]
130a NR +429
+428
NR NR +52
c
+53
c
NR Postma et al.
2006
aNumbers of patients in each group not specified.
bFP dose 37% higher to maintain blinding. 
cReported as a mean value. 
dLeast squares mean vs budesonide; intent-to-treat analysis.
eOpen-label design.
+, increase; –, decrease; A, AM; bid, twice daily; BUD, budesonide; CIC, ciclesonide; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; FP, fluticasone propionate; 
NR, not reported; P, PM; PRED, prednisolone; PEF, peak expiratory flow; qd, once daily; w, week.
Table 6 | Effect on lung function of ciclesonide compared with active treatment in patients aged >12 years with moderate to severe
asthma (level 2 evidence; all trials double-blind unless stated)evening administration of ciclesonide 320 mcg and budesonide
400 mcg, onset of treatment effect as evidenced by daily
recordings of morning PEF was observed on day 3 with
ciclesonide compared with week 2 with budesonide (Biberger et al.
2003). Differences between ciclesonide and active control were
not statistically significant. Similarly, maintenance of pulmonary
function with ciclesonide 160 mcg (dosed either in the morning or
evening) was not statistically different with budesonide 200 mcg
twice daily (Niphadkar et al. 2005). However, an 8-week study
reported in abstract form reported a significant difference (P=0.001)
in PEF in favour of ciclesonide 320 mcg twice daily compared with
budesonide 400 mcg twice daily (Adachi et al. 2006).
These results are predominantly obtained from studies of
12 weeks’ duration. In a 40-week open-label extension of a 
12-week double-blind study evaluating ciclesonide 800 mcg/day
and 1600 mcg/day, the improvement in FEV1 was sustained
throughout the study period (O'Connor et al. 2002). Over a 
52-week study period, FEV1 increased significantly over baseline
in patients treated with ciclesonide 200 mcg/day (P=0.0072) 
and 800 mcg/day (P=0.0237) (Chapman et al. 2002).
Finally, ciclesonide 640 mcg twice daily was as effective as 
oral prednisolone 40 mg once daily in improving lung function in 
130 patients with acute asthma exacerbation, without causing
HPA suppression (Postma et al. 2006).
Use of oral corticosteroids
Since the regular use of oral corticosteroids is associated with
significant adverse systemic effects, the impact of inhaled
corticosteroid therapy on daily oral corticosteroids required to
control symptoms in patients with persistent asthma is an
important measure of efficacy. Use of inhaled corticosteroids 
has been associated with a reduction in the use of oral
corticosteroids (Larj & Bleecker 2004). In a 12-week trial of 
141 patients with severe, persistent asthma, use of ciclesonide
significantly reduced the need for oral corticosteroid at doses of
320 or 640 mcg twice daily compared with placebo. Mean
percentage change in oral corticosteroid use from baseline was
–47.39 (low-dose ciclesonide, P=0.0003 vs placebo), –62.54
(high-dose ciclesonide, P=0.0001 vs placebo), and +4.2 (placebo) 
(Bateman et al. 2006b).
Asthma symptom score and use of rescue medications
Evidence from large controlled trials that have evaluated
ciclesonide and either placebo or a comparator drug indicate that
ciclesonide is at least as effective in reducing patient-reported
asthma symptoms and use of rescue medications (Table 7). 
For example, daily albuterol use as rescue medication was
reduced significantly in all ciclesonide-treated groups (80, 160,
and 320 mcg) but increased in the placebo group (Pearlman et al.
2005). A dose–response effect has been demonstrated, with half
as many patients receiving ciclesonide 320 mcg twice daily
experiencing an asthma exacerbation compared with those 
taking ciclesonide 160 mcg/day (23 [6.7%] vs 43 [12.7%]
patients) (Bateman et al. 2006a). The higher dose was also
associated with significantly lower use of rescue medication
(P=0.0005) and improved symptom scores (P=0.0108) than the
lower dose. 
In one study comparing inhaled doses of ciclesonide 80 mcg once
daily, ciclesonide 160 mcg once daily, and fluticasone propionate
88 mcg twice daily in patients with mild-to-moderate persistent
asthma, the percentage of days without asthma symptoms and
without the need for rescue medications (84–87% for mild disease;
70–79% for moderate disease) was similar for all treatment groups
and was highest during the last 4 weeks of the 12-week study
(Magnussen et al. 2005). This increase in the last 4 weeks of a 12-
week trial was also observed by Buhl et al. (2005b). The percentage
of symptom-free days was higher in those patients treated with
ciclesonide (91%) than in patients treated with fluticasone (83%,
significance not reported), although the percentage of days not
requiring rescue medication was comparable (89 vs 91%,
respectively) (Buhl et al. 2005b). A full publication of this study by
the same authors reported comparable changes in asthma
symptom scores for ciclesonide and fluticasone (reductions of 0.75
and 0.86, respectively) (Buhl et al. 2005a). Ciclesonide 320 mcg
once daily was comparable to fluticasone 200 mcg twice daily in
percentage of days without symptoms (88% both groups) or use
of rescue medication (85 and 84%, respectively) after 12 weeks 
in 472 patients with moderate asthma (Boulet et al. 2006b).
Bateman et al. (2006c) adds to the evidence that ciclesonide is
equivalent in efficacy to fluticasone. 
Patients treated with ciclesonide 160 mcg (dosed either in the
morning or in the evening) or budesonide 200 mcg twice daily
experienced equivalent periods of symptom-free days (89, 91, and
93%, respectively) (Niphadkar et al. 2005). In addition, other
outcomes including rescue medication use, days with control of
asthma symptoms, and days without PEF fluctuation were
maintained versus baseline with no significant differences between
the three groups. In contrast, Adachi et al. (2006) reported
significantly lower use of rescue medication (P=0.007) and
improved symptom scores (P=0.008) with ciclesonide 320 mcg
twice daily compared with budesonide 400 mcg twice daily after 
8 weeks’ treatment in 319 patients with moderate to severe asthma.
Similarly, although overall judged as having comparable efficacy,
ciclesonide 320 mcg once daily resulted in significantly more
symptom-free days compared with budesonide 320 mcg once
daily in 359 patients with persistent asthma (Boulet et al. 2006a).
Use in children
The efficacy of ciclesonide in children has been compared with
placebo, budesonide, and fluticasone. 
In a large double-blind, randomized trial involving 1031 children
aged 4–11 years, mean FEV1 percent predicted increased by
11.97, 13.58, and 14.17, and mean absolute FEV1 increased by
250, 280, and 290 mL versus placebo after 12 weeks’ treatment
with ciclesonide 40, 80, and 160 mcg once daily, respectively
(Gelfand et al. 2006). Morning and evening PEF also increased,
the latter by 12.27, 18.34, and 15.78 L/min. The changes seen
with ciclesonide 80 and 160 mcg/day were significant versus
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Treatment (mcg)
[duration]
n Baseline FEV1
(% of predicted)
Outcome Reference
Symptom-free days (%) Use of rescue medication (puffs/day)
Placebo-controlled trials
CIC 80 qd 
CIC 320 qd 
Placebo
[12 w]
360 60–90 Median number of symptom-free days was
higher in patients treated with CIC vs
placebo
0a
0a
+0.5a
Langdon
et al. 2005
CIC 80 qd
CIC 160 qd
CIC 320 qd
Placebo
[12 w]
257
250
255
249
60–85 NR –0.86a (P≤0.001)
–1.02a (P≤0.001)
–1.04a (P≤0.001)
+0.42a
Pearlman
et al. 2005
CIC 320 bid
CIC 640 bid
Placebo
[12 w]
47
49
45
40–80 NR –0.07a
–0.08a
+0.32a
Bateman et
al. 2006b
Comparator trials
CIC 320 qd
BUD 400 qd
[12 w]
399 NR Similar between groups Similar between groups Biberger
et al. 2003 
CIC 160 qd
FP 88 bid
[12 w]
266
263
80–100 79
77
–1.00a
–1.21a
Buhl et al.
2004,
2005a,b
CIC 160 qd A
CIC 160 qd P
BUD 200 bid
[12 w]
139
131
133
≥70 89
91
93
Similar between groups Niphadkar
et al. 2005
CIC 320 qd
CIC 320 bid
BUD 400 bid
[8 w]
319 NR NR NR
–0.44c
NR
Adachi et al.
2006
CIC 320 bid
FP 330 bid
[24 w]
528 ≥80 Similar between groups Similar between groups Bateman et
al. 2006c
CIC 320 qd
BUD 320 qd
[12 w]
179
180
65–95 43.6d
25.8
57.5b
53.6b
Boulet et al.
2006a
CIC 320 qd
FP 200 bid
[12 w]
472 60–80 88
88
89b
88b
Boulet et al.
2006b
CIC 80 qd
CIC 320 qd
BUD 200 bid
[12 w]
182
195
177
73
72
72
Approx. 40% for all treatment groups –0.68a (P<0.001)
–1.00a (P<0.001)
–1.04a (P<0.001)
Hansel et al.
2006
CIC 640 bid
PRED 40 mg qd
[2 w]
130 NR Similar between groups Similar between groups Postma et al.
2006
aChange from baseline.
bPercentage of days without use.
cP=0.029 vs CIC 320qd, P=0.007 vs BUD.
dP=0.017.
+, increase; –, decrease; bid, twice daily; A, AM; BUD, budesonide; CIC, ciclesonide; FEV1, forced expiratory volume in 1 s; FP, fluticasone propionate; NR, not reported; P, PM; qd, once daily.
Table 7 | Effect on symptoms and use of rescue medications of ciclesonide compared with placebo and active treatment in patients
with asthma (level 2 evidence; all trials in adults, randomized)243
placebo. These improvements were associated with significantly
more symptom-free days among children receiving ciclesonide 
80 (52.44%; P<0.0001) and 160 mcg/day (48.77%; P=0.0139)
compared with placebo (42.52%), and significantly lower use of
rescue medication (P<0.01). Ciclesonide improved symptom
scores and reduced nighttime awakening at all three doses.
There is evidence that ciclesonide 160 mcg/day, given either as
a single dose or as 80 mcg twice daily, is as effective as
fluticasone 88 mcg twice daily and budesonide 400 mcg once
daily. In 556 children, ciclesonide and fluticasone increased
mean FEV1 by 298 and 297 mL, respectively, after 12 weeks
(Pedersen et al. 2004a). Corresponding increases in mean
morning and evening PEF were 31 and 29 L/min with ciclesonide,
and 34 and 29 L/min with fluticasone.
Mean FEV1 increased by 220 mL in 340 children aged 6–11 years
following 12 weeks’ treatment with ciclesonide and by 253 mL in
173 receiving budesonide (von Berg et al. 2006). Asthma
symptoms were absent in an almost identical proportion of days
in each group (74% for ciclesonide and 73% for budesonide), and
both drugs were comparable in improving symptom scores and
reducing rescue medication use.
Quality of life
HRQOL measures offer an important patient perspective into the
therapeutic management of asthma. Because asthma is a chronic
disease that may affect a patient’s ability to participate in 
normal daily activities including work, school, and extracurricular
activities, it is important to include the impact of a medication on
quality of life in a determination of its effectiveness and place in
therapy. There is often a disconnection between medication-
induced changes in airways as assessed by the clinician and
patient perceptions of their functional status. The effect of
treatment on HRQOL is now recognized as an important gauge of
therapy and should be used as a determinant of treatment effect.
HRQOL measurement provides the clinician with important insight
into the burden of disease and provides an appreciation of the
effect of treatment on functional status. Treatments with positive
HRQOL effects may improve patient compliance with therapy and
improve overall patient satisfaction (Gerth van Wijk 2005).
Although several HRQOL tools have been used to evaluate
HRQOL in patients with asthma, in the ciclesonide studies that
provided HRQOL information, the Asthma Quality of Life
Questionnaire (AQLQ) and the Pediatric Asthma Quality of Life
Questionnaire (PAQLQ) were the tools used for assessment. The
reliability and validity of the AQLQ has been verified in several
studies (Gupchup et al. 1997; van der Molen et al. 1997; Sanjuas
et al. 2002). The AQLQ is a 32-item, four-domain (symptoms,
emotional function, activity limitation, and breathlessness)
questionnaire that can be interviewer- or self-administered. Using
this questionnaire, a change in score of 0.5 is considered the
minimum change necessary for clinical significance. 
A separate pediatric-based questionnaire is necessary for
children because it is clear that conventional measures of the
effectiveness of therapy (asthma severity, spirometry, and
medication use) and parents’ perceptions of a child’s functionality
weakly correlate with how children actually feel and their ability 
to participate in activities of daily life (Juniper et al. 1996). 
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Treatment (mcg) n Baseline FEV1 (% of predicted) Outcome: patients achieving an MID (≥0.5) in QOL score (%) Reference
Studies in adults and adolescents aged >12 years
CIC 160 bid
CIC 320 bid
FP 440 bida
Placebo
531 40–65 42.5
43
58.8
26.8
Bernstein et al. 2005
CIC 80 qd
CIC 160 qd
CIC 320 qd
Placebo
1015 60–85 47
50
50.6
31
Nayak et al. 2005
Study in pediatric patients aged 7–17 years
CIC 40 qd
CIC 80 qd
CIC 160 qd
Placebo
793 60–85 46.1
50
52.5
36.5
Miller et al. 2005;
Gelfand et al. 2006
CIC 160 qd
BUD 400 qd
340
173
NR 53.8
50.6
Vermeulen et al. 2006
aFP dose 37% higher to maintain blinding.
bid, twice daily; BUD, budesonide; CIC, ciclesonide; FEV1, forced expiratory volume in 1 s; FP, fluticasone propionate; MID, minimally important difference; qd, once daily.
Table 8 | Effect on quality of life of ciclesonide compared with placebo or active treatment (level 2 evidence; all studies randomized,
multicenter, double-blind, parallel-group, placebo-controlled, 12 weeks’ duration)The PAQLQ is a 23-item questionnaire that is appropriate for
children between the ages of 7 and 17 years and focuses on three
domains (symptoms, emotional function, and activity limitation). 
A change in score of 0.5 reflects a minimally important difference.
Both interviewer- and self-administration formats of the PAQLQ
are available (Juniper 1997). 
The impact of ciclesonide on the HRQOL of patients with asthma
has been assessed (Table 8) (Bernstein et al. 2005; Miller et al.
2005; Nayak et al. 2005). In one study that included patients with
severe persistent asthma (FEV1 40–65%), clinically significant
changes in AQLQ (≥0.5) were noted in all three groups receiving
ciclesonide 160 or 320 mcg, or fluticasone 440 mcg twice daily
(Bernstein et al. 2005). The change in AQLQ with fluticasone was
greater than that noted with either dose of ciclesonide, although
the statistical significance of this difference was not reported.
These HRQOL studies were only conducted for a period of
12 weeks, therefore, it is not known if improvements in QOL are
sustainable or whether the changes translate to significant long-
term patient improvement. 
Tolerability
A major component of the rationale for the development of
ciclesonide is the minimization of local and systemic side effects
often experienced with inhaled corticosteroids. Ciclesonide has
been well tolerated in clinical trials with most adverse effects
reported as mild. It is anticipated that the airway activation of
ciclesonide will reduce the incidence of adverse effects compared
with currently available inhaled corticosteroids. Although there are
some data from longer term studies, the bulk of the evidence
supporting the lack of systemic effects with ciclesonide therapy is
limited to 12 weeks of treatment. Further long-term data will be
necessary to confirm if ciclesonide offers an advantage over the
other inhaled corticosteroids.
Local adverse effects 
Local adverse effects associated with the use of inhaled
corticosteroids include perioral dermatitis, tongue hypertrophy,
cough during inhalation, and sensation of thirst. The most
frequently reported clinically significant effects are oropharyngeal
candidiasis and dysphonia (Roland et al. 2004). Deposition of
active medication in the oropharyngeal cavity is dependent on the
delivery device and can be decreased with the use of spacers.
These adverse effects, while they are not considered to be
clinically serious, are troublesome and may affect patient
adherence (Goeman 2002).
Oropharyngeal deposition of ciclesonide (metered-dose inhaler with
hydrofluoroalkane propellant) is reduced compared with fluticasone
(metered-dose inhaler with hydrofluoroalkane propellant) and
budesonide (metered-dose inhaler with CFC) (Nave et al. 2005a;
Richter et al. 2005). This reduction in oral deposition is expected to
correlate with a lower rate of local adverse effects. In a pooled
analysis of phase II and phase III studies, data from 12 251 patients
who received ciclesonide (n=7706), active control [budesonide,
beclomethasone, or fluticasone (n=3330)], or placebo (n=1215) 
for 12 weeks were analyzed to determine the incidence of
oropharyngeal adverse events (candidiasis, hoarseness, cough)
(Engelstätter et al. 2005). The incidence of local adverse events per
patient year was similar in the ciclesonide and placebo group; oral
candidiasis and hoarseness occurred less frequently in the
ciclesonide group compared with the active control group (P value
not reported) (Table 9). In a subanalysis, fewer patients in the
ciclesonide group experienced an oral adverse event compared with
patients in the fluticasone subgroup (P<0.0001).
There is limited evidence that this lower frequency of oral adverse
effects is maintained when treatment exceeds 12 weeks. A single
open-label study that followed a 12-week placebo-controlled trial
reported oropharyngeal side effects in 10 of 228 patients treated
with ciclesonide (3.5%) (Chapman et al. 2002). After 24 weeks of
treatment in an open-label study involving 528 patients, oral
candidiasis or dysphonia were reported by 5.1% of patients
receiving ciclesonide 320 mcg twice daily, significantly less than
the 12.8% for fluticasone 330 mcg twice daily (P=0.0014)
(Bateman et al. 2006c).
Systemic adverse effects
Systemic effects of inhaled corticosteroids occur because a large
percentage (80%) of an administered dose of active drug is
swallowed (Roland et al. 2004). Additional systemic exposure can
occur as the drug is absorbed from the pulmonary fluid into the
systemic circulation (Hübner et al. 2005). The amount of drug that
is available to the systemic circulation, method of delivery, and
lipophilicity of the drug influence risk of systemic side effects. The
extent of systemic exposure with inhaled corticosteroids is
typically reported by the magnitude of HPA axis suppression,
serum and urinary cortisol concentrations, and effects on bone
growth or mineralization. Systemically active corticosteroids bind
to glucocorticoid receptors in the hypothalamus and adrenal
pituitary causing a decrease in the amount of corticotropin-
releasing hormone and adrenocorticotropic hormone leading to
decreased cortisol secretion (Lipworth et al. 2005). 
HPA axis suppression and cortisol levels
There is clear evidence that ciclesonide does not cause HPA axis
suppression after 12 weeks of treatment.
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Adverse event Incidence of event/patient year
Ciclesonide Placebo Active controlb
Candidiasis 0.02 0.02 0.07
Hoarseness 0.03 0.03 0.07
aCough not reported.
bBeclomethasone, budesonide, or fluticasone.
Table 9 | Incidence of oropharyngeal adverse events with
ciclesonide compared with placebo or active
treatmenta (adapted from Engelstätter et al. 2005)245
In a 12-week, double-blind, randomized, placebo-controlled
study assessing the systemic adverse effect potential of
ciclesonide, 164 patients were randomized to receive fluticasone
propionate (CFC propellant) 440 mcg daily, ciclesonide 320 mcg
once daily, ciclesonide 320 mcg twice daily, or placebo (Lipworth
et al. 2005). Serum and urine cortisol levels were measured at
baseline, week 6, and week 12. HPA axis function was preserved
with ciclesonide in doses of up to 640 mcg/day. After 12 weeks,
changes in mean peak serum cortisol levels and 24-hour 
urinary free cortisol levels following both doses of ciclesonide
were not significantly different from placebo, in contrast to
fluticasone propionate 880 mcg/day, which was associated with
significant reductions of 9–10% in peak serum cortisol levels 
and 60% in 24-hour urinary free cortisol levels (Lipworth et al.
2005). Other studies have also reported a lack of effect of
ciclesonide therapy on serum and 24-hour urinary free cortisol
corrected for creatinine (Postma et al. 2001; Pearlman et al. 2005).
In a 12-week study of once-daily inhaled ciclesonide 80 mcg
(n=182) or 320 mcg (n=195) compared with inhaled budesonide
200 mcg (n=177) twice daily, no relevant changes in 24-hour
urinary cortisol excretion were observed in patients receiving
ciclesonide. However, patients who received budesonide had a
statistically significant suppression of urine cortisol (P<0.05)
(Hansel et al. 2006).
Sixty adult patients were randomized in a single-center, double-
blind, double-dummy, parallel-group study evaluating HPA axis
suppression associated with the use of ciclesonide compared to
fluticasone in patients with moderate-to-severe asthma (Szefler et
al. 2005). Patients received either ciclesonide 320 mcg twice
daily, ciclesonide 640 mcg twice daily, fluticasone 440 mcg twice
daily, fluticasone 880 mcg twice daily, or placebo for 29 days.
Mean serum cortisol AUC0–24h at the end of treatment was
significantly suppressed in the high-dose fluticasone group. 
A cosyntropin stimulation test showed no statistically significant
differences among the groups. Twenty-four-hour urinary cortisol
levels were significantly increased from baseline at week 
4 compared with placebo in the ciclesonide 320 mcg twice-daily
group (P=0.0224; 95% confidence intervals 0.0023, 0.0283); the
other treatment groups did not demonstrate any change in urinary
cortisol levels (Szefler et al. 2005).
In addition, two abstracts report preliminary information on HPA
axis suppression with ciclesonide and an active control in adults
(Ukena et al. 2003) and in children (Pederson et al. 2004b). In the
study comparing ciclesonide 320 mcg/day with budesonide
400 mcg/day in adults, no relevant change in laboratory
parameters or urine cortisol were noted after 12 weeks of
treatment (Ukena et al. 2003). In the pediatric phase III comparator
study, the difference between urinary free cortisol levels in patients
treated with ciclesonide 80 mcg twice daily (+1.54 nmol/mmol
creatinine) versus patients treated with fluticasone propionate
88 mcg twice daily (–1.83 nmol/mmol creatinine) was statistically
significant (P=0.0062) (Pedersen et al. 2004b). 
The lack of suppressive effect appears to be independent of dose.
A study of high-dose ciclesonide 800 mcg/day substantiates the
lack of suppressive effect with ciclesonide. The HPA axis function
of 12 healthy volunteers was preserved after 800 mcg/day of
inhaled doses of ciclesonide (400 mcg twice daily, 800 mcg in the
morning, or 800 mcg in the evening) given for 7 days. The effect
was independent of time of administration (Weinbrenner et al.
2002). There is further evidence for the lack of effect on HPA axis
from 26 patients with asthma receiving ciclesonide 320 mcg once
daily, or 640 mcg once or twice daily, or fluticasone 440 mcg 
or 880 mcg twice daily in randomized, double-blind fashion for 
9 days (Derom et al. 2005). Although the study was short duration
and involved few patients, 24-hour cortisol secretion was
unaffected by ciclesonide, even at the high dose.
Furthermore, there is evidence that HPA axis suppression does
not appear to develop with longer-term ciclesonide treatment
(Chapman et al. 2002; O'Connor et al. 2002). In these placebo-
controlled ciclesonide trials, patients received an individualized
dose of ciclesonide for 40 weeks following the initial 12-week
study. Serum cortisol levels were increased compared with the
former steroid treatment (budesonide 800–2000 mcg/day or
equivalent) (O'Connor et al. 2002). There was no evidence 
that ciclesonide suppressed the HPA axis as evidenced by changes
in serum and urine cortisol measurements (Chapman et al. 2002).
Importantly, these long-term data have been replicated in 661
children aged 5–8.5 years, with ciclesonide 40 or 160 mcg/day
associated with minimal changes in urinary-free cortisol levels
after 1 year of treatment (Bernstein et al. 2006).
Bone mineralization and growth
Orally administered glucocorticoids are known to affect bone
mineralization, decrease osteocalcin concentration in healthy
volunteers, and decrease bone density in the lumbar spine (Jones et
al. 2002; van Staa et al. 2002). In young patients, these factors
impact bone growth. In adults, these effects can increase the risk of
fracture. Glucocorticoids assert their effect on bone predominantly
by decreasing bone formation through a negative effect on the
function and lifespan of osteoblasts (Jones et al. 2002). Despite the
limited systemic absorption of inhaled corticosteroids, the long-term
administration of these agents is also believed to impact bone
metabolism (Roland 2004; O’Connell 2005). Laboratory indices of
bone formation (bone-specific alkaline phosphatase and serum
osteocalcin) have been followed to quantify the impact of therapy. 
Over a 52-week study in patients with moderate-to-severe
asthma, increased levels of serum bone-specific alkaline
phosphatase and serum osteocalcin were observed in patients
after receiving ciclesonide compared with the levels obtained while
they were on their prestudy doses of steroid (P<0.05), suggesting
that the impact of ciclesonide treatment on bone metabolism in
these patients was significantly less than the effects of previously
used inhaled corticosteroid therapies (O'Connor et al. 2002). 
Studies measuring the effect of lower leg growth in children have
been reported. Twenty-four children aged 6–12 years were
randomized to receive a daily dose of ciclesonide 40 mcg,
80 mcg, 160 mcg, or placebo over a 12-week period. No
statistically significant differences in knemometry results, height
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patients (Agertoft & Pedersen 2005). Growth velocity was
unaffected by 1 year of treatment with ciclesonide in 661 children
aged 5–8.5 years (Skoner et al. 2006). During treatment, mean
linear growth velocity was 5.73 cm/year with ciclesonide
40 mcg/day, 5.6 cm/year with ciclesonide 160 mcg/day, and
5.75 cm/year with placebo. In the same patient cohort,
ciclesonide also had no effect on skeletal maturity, as measured
by chronologic to bone age ratio (Neffen et al. 2006). A shift from
normal to high ratio was seen in 17 patients, although a
treatment-related effect seems unlikely since fewer of those
taking higher-dose ciclesonide were affected (1.1%), and the
incidence with low-dose ciclesonide was similar to that with
placebo (4.3 and 4%).
Drug interaction potential
The pharmacokinetic properties of ciclesonide are such that
significant drug–drug interactions are not expected with its use.
Ciclesonide is activated in airways at the desired site of action
and very little of the drug is available to the systemic circulation.
A single pharmacokinetic study evaluating ciclesonide and
erythromycin coadministration demonstrated a lack of interaction
between these medications (Nave et al. 2005b). As with other
inhaled corticosteroids, drug–drug interactions are not
considered to be a clinical concern.
Resource utilization
At present, economic evidence comparing the use of
ciclesonide with other inhaled corticosteroids is not available.
Ciclesonide, from a clinical standpoint, appears comparable to
budesonide and fluticasone propionate, but with less propensity
for systemic adverse effects. It is possible that the once-daily
administration of ciclesonide coupled with its low adverse event
profile will give ciclesonide an advantage over other inhaled
corticosteroids. Use of ciclesonide over one of the other inhaled
corticosteroids will ultimately depend on additional long-term
data as they become available, including its long-term adverse
effect profile and impact on HRQOL. Economic data, including
the effect of ciclesonide treatment on both direct and indirect
medical costs, will need to be factored into the decision-making
process to determine its place in therapy with regard to the
other inhaled corticosteroids. 
In general, inhaled corticosteroids are considered the most
effective therapy for reducing asthma exacerbations and studies
have reported that the use of these agents reduce medical costs
and decrease the use of healthcare resources (Halpern 2003). 
A recent meta analysis examined the long-term effects of inhaled
corticosteroids, long-acting beta2 agonists, leukotriene pathway
modifiers/receptor antagonists, and antiimmunoglobulin E
antibody therapies. Of these agents, inhaled corticosteroids 
were found to have the greatest impact on the reduction of 
asthma exacerbations (55% vs placebo; relative risk 0.46, 
95% confidence intervals 0.34, 0.62; P<0.001) (Sin et al. 2004).
These reductions in exacerbations translate to economic savings
from decreased hospitalizations, decreased emergency room
visits, and a decrease in physician visits and use of rescue
medications. In order for an inhaled corticosteroid to produce its
positive effects, it must be used continuously to keep the
inflammatory process in check.
Patient group/population
Asthma affects all age groups, from pediatric patients to the
elderly. Available evidence for ciclesonide demonstrates efficacy
in patients with persistent asthma that is similar to other currently
available inhaled corticosteroids. Inhaled corticosteroids are the
mainstay of treatment for patients with persistent asthma. Any
patient with symptom frequency that suggests persistent disease
would benefit from maintenance treatment with an agent such as
ciclesonide. The evidence for a lack of effect on growth rate and
skeletal maturation in children in the long term (1 year) indicates
that ciclesonide is suitable for pediatric use.
Dosage, administration, and formulations
Ciclesonide (Alvesco®) is available in a 80 mcg and 160 mcg
metered-dose inhaler, with hydrofluoroalkane propellant.
Approved dosages and indications vary between different
countries, and readers are advised to consult their local
prescribing information (Anon. 2006). The recommended starting
dose is usually 160 mcg once daily, preferably in the evening.
Maintenance on 80 mcg once daily may be effective in some
patients. No dosage adjustment is necessary in the elderly or in
patients with hepatic or renal impairment.
Place in therapy
The unique pharmacokinetic profile of ciclesonide confers a
potential advantage in that there is minimal systemic absorption
of active drug, which appears to be sustained as shown by a
lack of HPA axis suppression after 1 year of treatment. Further
evidence will confirm if efficacy is sustained in the longer term
with approved doses, and if the decrease in systemic exposure
is linked to an overall increased safety profile. The decrease in
adverse effects that have been observed in short-term trials
may be beneficial in some patients for whom the local effects
are bothersome and may lead to disruptions in therapy. In
addition, patients with more severe disease who are being
treated with higher doses of inhaled corticosteroids may also
benefit because of the apparent decrease in systemic exposure
associated with ciclesonide use. The drug appears to have a role
in the management of pediatric patients with asthma, and is not
associated with growth retardation in long-term use.
The available evidence indicates that ciclesonide is as effective
as fluticasone and budesonide for the management of persistent
asthma, as shown by improvements in lung function parameters,
symptom scores, and use of rescue medications. Inhaled
corticosteroids are considered to be the foundation of asthma
management in patients with persistent disease (Table 2). 
It is expected that ciclesonide will be included in updated
guidelines as a primary therapy along with other inhaled
corticosteroids. Currently, the use of combination inhalers 
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(beta-agonist/corticosteroid) is recommended as a means to
streamline therapy in patients with persistent asthma. (Anon.
2005b; British Thoracic Society 2005). Ciclesonide is not
available in a combination formulation and therefore patients
would be required to have two separate inhalers. There is
evidence that lung function improvements are maintained for up
to 1 year of treatment. 
The impact of ciclesonide use on overall disease course, DALYs,
and hospitalization rate as compared with other currently
available inhaled corticosteroids has not been reported. These
measures are important to the overall evaluation of the expected
role of ciclesonide in the management of persistent asthma.
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